Literature DB >> 25467557

Health related quality of life (HRQOL) in long-term survivors of pediatric low grade gliomas (LGGs).

Chika R Nwachukwu1, Ryan S Youland, Catherine Chioreso, Nicholas Wetjen, Amulya NageswaraRao, Gesina Keating, Nadia N Laack.   

Abstract

The purpose of this study was to assess the health-related quality of life (HRQOL) and the impact of treatment on HRQOL in long-term survivors of pediatric low-grade gliomas (LGGs) using an adult instrument. QOL of 121 patients with a diagnosis of LGG from the Mayo Clinic were assessed using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ-C30 for cancer in general) and (EORTC QLQ-BN20 specific for brain tumors). Median follow-up was 21.9 years for the participants. Median age at diagnosis was 11.8 years and at assessment was 33 years. Mean (standard deviation) global QOL score for the study was 78 (18) and 76.4 (22.8) in a reference population of healthy adults. Using QLQ-C30, radiation treated patients compared to non-radiation patients reported lower physical functioning (p = 0.002), role functioning (p = 0.004), and more constipation problems (p < 0.001). Patients with tumor recurrence reported lower role functioning (p = 0.016), social functioning (p = 0.040), and more financial problems (p = 0.029) compared to their counterparts. Using QLQ-BN20, patients with deep tumors compared to cortical tumors reported more bladder control problems (p = 0.016). Radiation treated patients also reported more bladder control problems (p < 0.001) compared to their counterparts. In the multivariable analysis, radiation therapy remained an independent predictor of physical and role functioning as well as symptoms related to brain tumors like visual disorders and motor dysfunction. Global QOL of long-term survivors of pediatric LGGs is similar to that of a reference population of healthy adults. The following tumor and treatment related factors were most consistently associated with poorer QOL: CNS tumor location, post-operative radiation, and tumor recurrence. Future studies are necessary to identify strategies to improve QOL in this subgroup of patients.

Entities:  

Mesh:

Year:  2014        PMID: 25467557      PMCID: PMC4323958          DOI: 10.1007/s11060-014-1673-1

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  37 in total

1.  Cognitive function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.

Authors:  Nadia N Laack; Paul D Brown; Robert J Ivnik; Alfred F Furth; Karla V Ballman; Julie E Hammack; Robert M Arusell; Edward G Shaw; Jan C Buckner
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-20       Impact factor: 7.038

2.  Cognitive functions and quality of life in patients with low-grade gliomas: the impact of radiotherapy.

Authors:  M J Taphoorn; A K Schiphorst; F J Snoek; J Lindeboom; J G Wolbers; A B Karim; P C Huijgens; J J Heimans
Journal:  Ann Neurol       Date:  1994-07       Impact factor: 10.422

3.  Health status and health-related quality of life in long-term adult survivors of pediatric solid tumors.

Authors:  D B Crom; D K Chathaway; E A Tolley; R K Mulhern; M M Hudson
Journal:  Int J Cancer Suppl       Date:  1999

4.  Sleep dysfunction in patients with cancer.

Authors:  Lavinia Fiorentino; Sonia Ancoli-Israel
Journal:  Curr Treat Options Neurol       Date:  2007-09       Impact factor: 3.598

5.  Sleep disturbance in cancer patients.

Authors:  Judith R Davidson; Alistair W MacLean; Michael D Brundage; Karleen Schulze
Journal:  Soc Sci Med       Date:  2002-05       Impact factor: 4.634

6.  Outcome and prognostic features in pediatric gliomas: a review of 6212 cases from the Surveillance, Epidemiology, and End Results database.

Authors:  Ibrahim Qaddoumi; Iyad Sultan; Amar Gajjar
Journal:  Cancer       Date:  2009-12-15       Impact factor: 6.860

7.  Changes in presentation, treatment, and outcomes of adult low-grade gliomas over the past fifty years.

Authors:  Ryan S Youland; David A Schomas; Paul D Brown; Chika Nwachukwu; Jan C Buckner; Caterina Giannini; Ian F Parney; Nadia N Laack
Journal:  Neuro Oncol       Date:  2013-06-27       Impact factor: 12.300

8.  Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.

Authors:  Dorle Messerer; Jutta Engel; Joerg Hasford; Markus Schaich; Gerhard Ehninger; Cristina Sauerland; Thomas Büchner; Andrea Schumacher; Rainer Krahl; Dietger Niederwieser; Jürgen Krauter; Arnold Ganser; Ursula Creutzig; Hartmut Döhner; Richard F Schlenk
Journal:  Haematologica       Date:  2008-05-10       Impact factor: 9.941

9.  Brain activity measured by functional magnetic resonance imaging is related to patient reported urgency urinary incontinence severity.

Authors:  Stasa D Tadic; Derek Griffiths; Werner Schaefer; Cathy I Cheng; Neil M Resnick
Journal:  J Urol       Date:  2010-01       Impact factor: 7.450

10.  Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice.

Authors:  Ashwini Budrukkar; Rakesh Jalali; Debnarayan Dutta; Rajiv Sarin; Rashmi Devlekar; Sachin Parab; Anagha Kakde
Journal:  J Neurooncol       Date:  2009-06-23       Impact factor: 4.130

View more
  8 in total

1.  Quality of life in long-term survivors treated for metastatic medulloblastoma with a hyperfractionated accelerated radiotherapy (HART) strategy.

Authors:  L Veneroni; L Boschetti; F Barretta; C A Clerici; F Simonetti; E Schiavello; V Biassoni; F Spreafico; L Gandola; E Pecori; B Diletto; G Poggi; F Gariboldi; R Sensi; M Massimino
Journal:  Childs Nerv Syst       Date:  2017-08-02       Impact factor: 1.475

Review 2.  Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas.

Authors:  María Baro Fernández; Vanesa Pérez Alonso
Journal:  Childs Nerv Syst       Date:  2016-09-20       Impact factor: 1.475

Review 3.  Pediatric low-grade gliomas: next biologically driven steps.

Authors:  David T W Jones; Mark W Kieran; Eric Bouffet; Sanda Alexandrescu; Pratiti Bandopadhayay; Miriam Bornhorst; David Ellison; Jason Fangusaro; Michael J Fisher; Nicholas Foreman; Maryam Fouladi; Darren Hargrave; Cynthia Hawkins; Nada Jabado; Maura Massimino; Sabine Mueller; Giorgio Perilongo; Antoinette Y N Schouten van Meeteren; Uri Tabori; Katherine Warren; Angela J Waanders; David Walker; William Weiss; Olaf Witt; Karen Wright; Yuan Zhu; Daniel C Bowers; Stefan M Pfister; Roger J Packer
Journal:  Neuro Oncol       Date:  2018-01-22       Impact factor: 12.300

Review 4.  Cognitive impact of lower-grade gliomas and strategies for rehabilitation.

Authors:  Christina Weyer-Jamora; Melissa S Brie; Tracy L Luks; Ellen M Smith; Steve E Braunstein; Javier E Villanueva-Meyer; Paige M Bracci; Susan Chang; Shawn L Hervey-Jumper; Jennie W Taylor
Journal:  Neurooncol Pract       Date:  2020-11-04

5.  Severe fatigue after treatment for childhood cancer.

Authors:  Sylvia van Deuren; Amilie Boonstra; Eline van Dulmen-den Broeder; Nicole Blijlevens; Hans Knoop; Jacqueline Loonen
Journal:  Cochrane Database Syst Rev       Date:  2020-03-03

6.  Determinants of impairments in functioning, fatigue, and participation ability in pediatric brain tumor survivors.

Authors:  Emma J Verwaaijen; Coriene E Catsman-Berrevoets; Heleen Maurice-Stam; Arianne B Dessens; Richelle Waslander; Tabitha P L van den Adel; Saskia M F Pluijm; Roel E Reddingius; Erna Michiels; Marry M van den Heuvel-Eibrink; Annelies Hartman
Journal:  Neurooncol Adv       Date:  2021-11-03

7.  Influences on cognitive outcomes in adult patients with gliomas: A systematic review.

Authors:  Matthew A Kirkman; Benjamin H M Hunn; Michael S C Thomas; Andrew K Tolmie
Journal:  Front Oncol       Date:  2022-08-05       Impact factor: 5.738

Review 8.  Management of Gliomas: Overview of the Latest Technological Advancements and Related Behavioral Drawbacks.

Authors:  L Ganau; M Paris; G K Ligarotti; M Ganau
Journal:  Behav Neurol       Date:  2015-08-09       Impact factor: 3.342

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.